Ouyang G, Liu Q, Wu Y, Liu Z, Lu W, Li S, et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the global burden of disease study 2017. Cancer. 2021;127:2238–50. https://doi.org/10.1002/cncr.33476.

Article  PubMed  Google Scholar 

Yang XW, Yang J, Li L, Man XB, Zhang BH, Shen F, et al. Analysis of the relationships between clinicopathologic factors and survival in gallbladder cancer following surgical resection with curative intent. PLoS ONE. 2012;7:e51513. https://doi.org/10.1371/journal.pone.0051513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23:3978–98. https://doi.org/10.3748/wjg.v23.i22.3978.

Article  PubMed  PubMed Central  Google Scholar 

Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357.

Article  PubMed  PubMed Central  Google Scholar 

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. https://doi.org/10.1056/NEJMoa0908721.

Article  CAS  PubMed  Google Scholar 

Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, et al. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2011;67:519–25. https://doi.org/10.1007/s00280-010-1351-8.

Article  CAS  PubMed  Google Scholar 

Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer. 2004;90:1516–20. https://doi.org/10.1038/sj.bjc.6601736.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31. https://doi.org/10.1007/s10439-005-8981-8.

Article  CAS  PubMed  Google Scholar 

Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25:997–1011. https://doi.org/10.1016/j.jvir.2014.01.028.

Article  PubMed  Google Scholar 

Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans Biomed Eng. 2015;62:4–20. https://doi.org/10.1109/TBME.2014.2367543.

Article  PubMed  Google Scholar 

Narayanan G, Froud T, Suthar R, Barbery K. Irreversible electroporation of hepatic malignancy. Semin Intervent Radiol. 2013;30:67–73. https://doi.org/10.1055/s-0033-1333655.

Article  PubMed  PubMed Central  Google Scholar 

Wagstaff PG, Buijs M, van den Bos W, de Bruin DM, Zondervan PJ, de la Rosette JJ, et al. Irreversible electroporation: state-of-the-art. Onco Targets Ther. 2016;9:2437–46. https://doi.org/10.2147/OTT.S88086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther. 2010;10:729–46. https://doi.org/10.1586/era.10.43.

Article  PubMed  Google Scholar 

Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS ONE. 2013;8(3):e59557. https://doi.org/10.1371/journal.pone.0059557.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J. Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol. 2014;37:1523–9. https://doi.org/10.1007/s00270-014-0988-9.

Article  PubMed  Google Scholar 

Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:43687. https://doi.org/10.1038/srep43687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience. Cardiovasc Intervent Radiol. 2019;42:584–90. https://doi.org/10.1007/s00270-019-02164-2.

Article  PubMed  Google Scholar 

Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275–81. https://doi.org/10.21037/jgo.2018.01.14.

Article  PubMed  PubMed Central  Google Scholar 

Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486–94. https://doi.org/10.1097/SLA.0000000000001441.

Article  PubMed  Google Scholar 

Canvasser NE, Sorokin I, Lay AH, Morgan MSC, Ozayar A, Trimmer C, et al. Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series. World J Urol. 2017;35:1549–55. https://doi.org/10.1007/s00345-017-2025-5.

Article  PubMed  Google Scholar 

Trimmer CK, Khosla A, Morgan M, Stephenson SL, Ozayar A, Cadeddu JA. Minimally invasive percutaneous treatment of small renal tumors with irreversible electroporation: a single-center experience. J Vasc Interv Radiol. 2015;26:1465–71. https://doi.org/10.1016/j.jvir.2015.06.028.

Article  PubMed  Google Scholar 

van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2018;121:716–24. https://doi.org/10.1111/bju.13983.

Article  CAS  PubMed  Google Scholar 

Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS ONE. 2019;14:e0215093. https://doi.org/10.1371/journal.pone.0215093.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, et al. High-voltage pulses in oncology: Irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology. 2020;295:254–72. https://doi.org/10.1148/radiol.2020192190.

Article  PubMed  Google Scholar 

Calvet CY, Mir LM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev. 2016;35:165–77. https://doi.org/10.1007/s10555-016-9615-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campana LG, Miklavčič D, Bertino G, Marconato R, Valpione S, Imarisio I, et al. Electrochemotherapy of superficial tumors—current status: basic principles, operating procedures, shared indications, and emerging applications. Semin Oncol. 2019;46:173–91. https://doi.org/10.1053/j.seminoncol.2019.04.002.

Article  PubMed  Google Scholar 

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and Elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

Article  PubMed  PubMed Central  Google Scholar 

Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer—a systematic review. Eur J Surg Oncol. 2019;45:83–91.